Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

Mesoblast Limited (LWB.F)

Compare

1.3900

-0.0300

(-2.11%)

At close: February 28 at 3:29:01 PM GMT+1

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Financial Results and Operational Update for Half-Year Ended December 31, 2024NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2024, “Our FDA approved product Ryoncil® will be available in the coming weeks to the children with SR-aGvHD in need of life-saving therapy,” said Dr. Silviu Itescu, Chi

GlobeNewswire 4 days ago

MEOBF
0.00%
MESO
Mesoblast Financial Results and Corporate Update Webcast

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2024. The webcast will begin at 5.00pm EST, Wednesday, February 26th; 9.00am AEDT, Thursday, February 27th, 2025. It can be accessed via: https://webcast.openbriefing.com/msb-hyr-2025/ The archived webcast will be available on

GlobeNewswire 5 days ago

MEOBF
0.00%
MESO
Dr. Gregory George MD PhD Joins Mesoblast Board

NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast’s largest shareholder, to its Board of Directors. Dr. George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George brings to the Board his background as a medical scientist with u

GlobeNewswire 7 days ago

MEOBF
0.00%
MESO
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com

GlobeNewswire 11 days ago

HGRAF

AEMD

GOSS
Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently approved product Ryoncil® (remestemcel-L) is being highlighted at the 2025 Transplantation & Cellular Therapy Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR), the industry’s premier conference takin

GlobeNewswire 17 days ago

MEOBF
0.00%
MESO
Domino's Pizza Enterprises And 2 Other ASX Stocks That Might Be Trading Below Fair Value

The Australian market has recently shown positive momentum, with the ASX200 closing up 0.6% at 8,535 points, driven by strong performances in the Industrials and Financials sectors. As investors navigate these shifting landscapes, identifying undervalued stocks like Domino's Pizza Enterprises and others could offer potential opportunities for those seeking value in a buoyant yet selective market environment.

Simply Wall St. 18 days ago

NCK.AX

MEOBF
0.00%
MESO
High Growth Tech Stocks in Australia Featuring FINEOS Corporation Holdings and Two Others

The Australian market has recently shown signs of recovery, with the ASX200 rising by 0.5% to reach 8,430 points, and the IT sector leading gains at 1.6%. In this context of renewed optimism and sectoral strength, high growth tech stocks like FINEOS Corporation Holdings offer intriguing opportunities for investors seeking exposure to innovative companies in a rebounding market environment.

Simply Wall St. 26 days ago

PPS.AX

FNCHF

MEOBF
0.00%
Ryoncil® Commercial Launch Update and Product Pipeline

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the progress of the U.S. commercial launch of Ryoncil® (remestemcel-L) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months and older and key upcoming milestones for its late-stage pipeline. ”We are committed to making our FDA approved product Ryoncil® available as qu

GlobeNewswire last month

MEOBF
0.00%
MESO
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the second quarter ended December 31, 2024. ACTIVITY REPORT On December 18, 2024, Ryoncil® (remestemcel-L) became the first mesenchymal stromal cell (MSC) therapy approved by U.S. FDA for any indication.FDA approved Ryoncil® as the first and only therapy for children aged 2 months and

GlobeNewswire last month

MEOBF
0.00%
MESO
3 ASX Growth Stocks With High Insider Ownership Seeing Up To 55% Earnings Growth

As the ASX200 experiences its third consecutive weekly gain, buoyed by a softer US stance on tariffs and calls for lower oil prices and interest rates, investors are keenly observing sectors like Discretionary and Real Estate that have shown robust performance. In this favorable environment, growth companies with substantial insider ownership can offer unique insights into potential earnings expansion, as insiders' vested interests often align closely with shareholder value creation.

Simply Wall St. last month

MEOBF
0.00%
MESO

ABB.AX
Bullish Mesoblast Insiders Loaded Up On US$145.4m Of Stock

Multiple insiders secured a larger position in Mesoblast Limited ( ASX:MSB ) shares over the last 12 months. This is...

Simply Wall St. last month

MEOBF
0.00%
MESO
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.

Zacks last month

MSB.AX
+3.17%
CSTL

CTMX
Exploring 3 High Growth Tech Stocks In Australia

The Australian market is experiencing a cautious start to the year, with the ASX 200 expected to open slightly lower amid global uncertainties and a weakening Aussie dollar, reflecting broader concerns about economic data and interest rate projections. In this environment, identifying high-growth tech stocks requires careful consideration of factors such as innovative potential and resilience in fluctuating market conditions.

Simply Wall St. last month

MEOBF
0.00%
MESO

CLVLF
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.

Zacks 2 months ago

MNPR

ARQT

MSB.AX
+3.17%
Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval

Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech stock rocketed.

Investor's Business Daily 2 months ago

MEOBF
0.00%
MESO
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft versus host disease. Shares rise.

Zacks 2 months ago

MSB.AX
+3.17%
INCY
FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment

This is the only MSC therapy approved in the US for any indication.

Pharmaceutical Technology 2 months ago

MSB.AX
+3.17%
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

On Wednesday, the FDA approved Mesoblast Limited’s (NASDAQ:MESO) Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is the only MSC therapy approved in the U.S. for any indication and the only therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older, including adolescents. Ryoncil contains MSCs, a type of cell that can have various roles in the body and can differentiate into multiple other types of cell

Benzinga 2 months ago

MSB.AX
+3.17%
Mesoblast to be Added to Nasdaq Biotechnology Index

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq index. Mesoblast’s inclusion in the NBI will be effective after the U.S. market opens on Monday, December 23, 2024. The Nasdaq Biotechnology Index contains securities of Nasdaq-listed companies clas

GlobeNewswire 2 months ago

MEOBF
0.00%
MESO
DREAM-HF trial sheds positive light on Revascor for ischemic HF

GlobalData believes that the study could be of high clinical value to cardiologists.

Clinical Trials Arena 2 months ago

MSB.AX
+3.17%
GLDAF

Performance Overview

Return	LWB.F	S&P/ASX 200 [XJO]
YTD	-19.19%	+0.49%
1-Year	+814.47%	+5.99%
3-Year	+106.24%	+15.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mesoblast Limited (LWB.F)

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Mesoblast Financial Results and Corporate Update Webcast

Dr. Gregory George MD PhD Joins Mesoblast Board

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

Domino's Pizza Enterprises And 2 Other ASX Stocks That Might Be Trading Below Fair Value

High Growth Tech Stocks in Australia Featuring FINEOS Corporation Holdings and Two Others

Ryoncil® Commercial Launch Update and Product Pipeline

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

3 ASX Growth Stocks With High Insider Ownership Seeing Up To 55% Earnings Growth

Bullish Mesoblast Insiders Loaded Up On US$145.4m Of Stock

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Exploring 3 High Growth Tech Stocks In Australia

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Mesoblast to be Added to Nasdaq Biotechnology Index

DREAM-HF trial sheds positive light on Revascor for ischemic HF

Performance Overview